The Manila Times

MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum

High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell ...
PharmiWeb

Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

Sixth overall for Lantern’s A.I.-driven precision oncology pipelineOrphan designation expands LP-284's potential for an ...

MAIA Biotechnology, Inc.: MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum

High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA's Fast Track designation for ateganosine ...
eLife

Rapid evolution of fine-scale recombination during domestication: a perspective from population genomics

Recombination serves as a pivotal force propelling the evolution of genomic diversity in sexually reproducing organisms. Despite its fundamental role, the evolutionary dynamics of recombination rates ...